3 Banking Software Company, Global Pharmaceuticals Company and Cement Maker Stocks With a Strong Future Roadmap: Oracle Financial Services Software, Sun Pharma and Star Cement
- November 13, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Oracle Financial Services Software, Sun Pharma and Star Cement: ROE of 12.3% to 33.7% and FY22 to FY26 revenue CAGR of 10.4% to 13.9%. Prices as of 12 Nov 2026.
Quick Answer
The three banking software, medicines and cement stocks to watch are Oracle Financial Services Software, Sun Pharma and Star Cement. Their return on equity ranges from 12.3% to 33.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.4% to 13.9%. Oracle Financial Services Software has the highest return on equity at 33.7%, while Star Cement has the fastest revenue growth at 13.9% a year. Prices are based on the 12 November 2026 close, and this article is educational, not investment advice.
Banking software, medicines and cement stocks offer a focused view of a sector where demand keeps widening. Oracle Financial Services Software, Sun Pharma and Star Cement cover a banking software company, a global pharmaceuticals company and a cement maker.
This list covers three banking software, medicines and cement stocks with complete current figures: Oracle Financial Services Software, Sun Pharma and Star Cement. Every figure comes from the latest reported financials and the 12 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Banking Software, Medicines and Cement Stocks?
Banking software, medicines and cement stocks are listed companies that build software products for banks and insurers, make and sell medicines across the world, and make cement for homes, roads and infrastructure. Their earnings depend on technology spending, medicine demand and construction activity.
Banking Software, Medicines and Cement Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Oracle Financial Services Software | 10,000 | 86,056 | 25.2 | 17.9 | 33.7 | 0.00 |
| Sun Pharma | 1,885 | 422,283 | 34.9 | 36.2 | 13.7 | 0.06 |
| Star Cement | 176.21 | 6,481 | 17.7 | 29.6 | 12.3 | 0.19 |
On valuation, Sun Pharma and Star Cement trade at a P/E below the industry P/E, while Oracle Financial Services Software trades above it, which reflects the growth the market already expects. Readers comparing banking software, medicines and cement stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Banking Software, Medicines and Cement Stocks Have a Strong Roadmap in India?
Banking software, medicines and cement stocks have a strong roadmap in India because rising digital spending by financial firms, growing demand for specialty medicines and heavy investment in roads and housing keep widening the market for these companies.
- Banking software. Financial firms modernise their systems.
- Pharmaceuticals. Patients need specialty medicines.
- Cement. Roads and homes need cement.
Why Oracle Financial Services Software Features Among These Banking Software, Medicines and Cement Stocks
Among the banking software, medicines and cement stocks on this list, Oracle Financial Services Software develops banking software products such as core banking, lending and risk platforms and also provides related services and support to banks and financial institutions around the world.
Revenue rose from Rs 5,356 crore in FY22 to Rs 7,943 crore in FY26, a compound annual growth rate of 10.4%. Net profit grew from Rs 1,889 crore in FY22 to Rs 2,639 crore in FY26, which works out to a compound annual growth rate of 8.7%.
The company has a return on equity of 33.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 86,056 crore. The stock trades at a P/E of 25.2, above the industry P/E of 17.9.
Roadmap: The company is helping banks move to modern platforms and cloud deployments, which creates demand for its products. Recurring licence and maintenance income supports earnings visibility.
What to watch: Follow product licence wins, cloud adoption by banking clients and the pace of new deals.
Why Sun Pharma Features Among These Banking Software, Medicines and Cement Stocks
Among the software products, global pharma and building material shares on this list, Sun Pharmaceutical Industries is India’s largest pharmaceutical company by market value, with branded generics in India, generics in the United States and a growing specialty medicines business for skin and eye care.
The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2.
Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore.
Roadmap: The company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
What to watch: Track specialty product launches, United States approvals and domestic prescription trends.
Why Star Cement Features Among These Banking Software, Medicines and Cement Stocks
Among the three companies on this list, Star Cement is a leading cement maker in India’s North East, producing cement at plants in Meghalaya and Assam and selling across the region and in eastern India.
Revenue rose from Rs 2,255 crore in FY22 to Rs 3,796 crore in FY26, a compound annual growth rate of 13.9%. Net profit grew from Rs 247 crore in FY22 to Rs 390 crore in FY26, which works out to a compound annual growth rate of 12.2%.
In the June 2026 quarter, revenue grew 4.1% year on year to Rs 951 crore. The company has a return on equity of 12.3%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 6,481 crore. The stock trades at a P/E of 17.7, below the industry P/E of 29.6.
Roadmap: The company is expanding capacity and widening its reach in eastern India, while infrastructure and housing spending in the North East supports demand. Its strong regional position helps pricing.
What to watch: Follow regional cement prices, capacity expansion and fuel and freight costs.
Oracle Financial Services Software vs Sun Pharma vs Star Cement on Key Financials
The table below sets the three banking software, medicines and cement stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Oracle Financial Services Software | 5,356 | 7,943 | 10.4% | 2,639 | 33.2% |
| Sun Pharma | 39,730 | 61,674 | 11.6% | 11,565 | 18.8% |
| Star Cement | 2,255 | 3,796 | 13.9% | 390 | 10.3% |
Oracle Financial Services Software posts the highest return on equity in this group at 33.7%. Sun Pharma has the largest FY26 revenue at Rs 61,674 crore, and Star Cement shows the fastest revenue growth with a 13.9% compound annual rate. A useful habit with banking software, medicines and cement stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Banking Software, Medicines and Cement Stocks
Every theme carries risks that deserve a check before any decision. For these banking software, medicines and cement stocks, the main points are: Long-term software products, global pharma and building material shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Currency moves. Export earnings move with the rupee.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Production cycles. Vehicle output can vary with demand.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter banking software, medicines and cement stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Banking Software, Medicines and Cement Stocks
Banking software, medicines and cement stocks reward patient research into demand, execution and financial strength. Oracle Financial Services Software, Sun Pharma and Star Cement each have a clear plan to grow. Based on the 12 November 2026 close, Oracle Financial Services Software trades at Rs 10,000, Sun Pharma at Rs 1,885 and Star Cement at Rs 176.21.
Download the Univest iOS App or Univest Android App to track banking software, medicines and cement stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are banking software, medicines and cement stocks?
Ans. Banking software, medicines and cement stocks are listed companies that build software products for banks and insurers, make and sell medicines across the world, and make cement for homes, roads and infrastructure. Their earnings depend on technology spending, medicine demand and construction activity. This list looks at three of them, Oracle Financial Services Software, Sun Pharma and Star Cement, using reported FY22 to FY26 financials and the 12 November 2026 closing prices.
Which banking software, medicines and cement stocks are covered in this list?
Ans. This list covers Oracle Financial Services Software, Sun Pharma and Star Cement. Based on the 12 November 2026 close, Oracle Financial Services Software traded at Rs 10,000, Sun Pharma at Rs 1,885 and Star Cement at Rs 176.21. Their return on equity ranges from 12.3% to 33.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.4% to 13.9%.
Why do banking software, medicines and cement stocks have a strong future roadmap in India?
Ans. Banking software, medicines and cement stocks have a strong roadmap in India because rising digital spending by financial firms, growing demand for specialty medicines and heavy investment in roads and housing keep widening the market for these companies. The main drivers are as follows. Banking software. Financial firms modernise their systems. Pharmaceuticals. Patients need specialty medicines. Cement. Roads and homes need cement. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Oracle Financial Services Software performed financially?
Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,943 crore in FY26, a compound annual growth rate of 10.4%. Net profit grew from Rs 1,889 crore in FY22 to Rs 2,639 crore in FY26, which works out to a compound annual growth rate of 8.7%. The company has a return on equity of 33.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 86,056 crore. The stock trades at a P/E of 25.2, above the industry P/E of 17.9. Looking ahead, the company is helping banks move to modern platforms and cloud deployments, which creates demand for its products. Recurring licence and maintenance income supports earnings visibility.
How has Sun Pharma performed financially?
Ans. Revenue rose from Rs 39,730 crore in FY22 to Rs 61,674 crore in FY26, a compound annual growth rate of 11.6%. Net profit grew from Rs 3,406 crore in FY22 to Rs 11,565 crore in FY26, which works out to a compound annual growth rate of 35.7%. In the June 2026 quarter, revenue grew 11.9% year on year to Rs 16,024 crore, while net profit rose 26.4% to Rs 2,911 crore. The company has a return on equity of 13.7%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 422,283 crore. The stock trades at a P/E of 34.9, below the industry P/E of 36.2. Looking ahead, the company is building its specialty portfolio and widening its range of complex generics, while its domestic branded business leads several prescription segments. A global manufacturing network supports supply across many markets.
How has Star Cement performed financially?
Ans. Revenue rose from Rs 2,255 crore in FY22 to Rs 3,796 crore in FY26, a compound annual growth rate of 13.9%. Net profit grew from Rs 247 crore in FY22 to Rs 390 crore in FY26, which works out to a compound annual growth rate of 12.2%. In the June 2026 quarter, revenue grew 4.1% year on year to Rs 951 crore. The company has a return on equity of 12.3%, a debt to equity ratio of 0.19 and a market capitalisation of Rs 6,481 crore. The stock trades at a P/E of 17.7, below the industry P/E of 29.6. Looking ahead, the company is expanding capacity and widening its reach in eastern India, while infrastructure and housing spending in the North East supports demand. Its strong regional position helps pricing.
What risks should investors check before buying banking software, medicines and cement stocks?
Ans. Investors should check a few risks before buying banking software, medicines and cement stocks. Currency moves. Export earnings move with the rupee. Regulatory approvals. Plant inspections and approvals can affect supplies. Production cycles. Vehicle output can vary with demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of banking software, medicines and cement stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 12 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
